/
ARVN
$9.01+$0.14 (+1.58%)live
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
1
institution
Market cap
$580.0M
65M shares
52-week range
$6.83 – $14.51
28% from low
Sector
PHARMACEUTICAL PREPARATIONS
Exchange
NASDAQ
CS
Change$-77.89
Arvinas, Inc
Arvinas Inc is a clinical-stage biotechnology company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development, and commercialization of therapies that degrade disease-causing proteins. The company is using its PROteolysis TArgeting Chimera, a protein degradation platform, to develop therapeutics designed to harness the body's own natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. Its clinical development program includes various product candidates such as ARV-102, ARV-806, ARV-393, ARV-027, and vepdegestrant, in their different stages of development, being developed to target certain harmful proteins causing oncology and neurology-related diseases.
www.arvinas.com- Employees
- 246
- IPO / List date
- Sep 27, 2018
- HQ
- NEW HAVEN, CT
Held by traders on TradeandTell
No one on the platform currently holds ARVN.
Super investors & insiders
Institutions holding (13F)
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2025-09-30 | 669,655 | $5.7M |
Insider activity (SEC Form 4)
Recent trades on TradeandTell
No one on the platform has traded ARVN yet.
